Effectiveness of Curcumin in patients with Parkinson's disease

Evaluation of Curcumin as add-on therapy in patients with Parkinson's disease on MDS-UPDRS scale: A Randomized Double-blind Placebo-controlled Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171123037600N1

Enrollment

Registered

2018-06-08

Start date

2018-05-22

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease. Parkinson's disease

Interventions

Intervention 1: Intervention group: Curcumin in form of nanomicelles (SinaCurcumin) as add-on therapy for 9 months with 80mg/day dosage. Intervention 2: Control group: Placebo drug identical to SinaCu

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who are diagnosed with Parkinson's disease based on MDS clinical diagnostic criteria for Parkinson's disease and at least 30 years of age Patients who are receiving dopaminergic treatment and their symptoms are under control Patients with signed informed consent

Exclusion criteria

Exclusion criteria: Severe systemic or psychologic disease History of Gastrointestinal bleeding Aspirin use over 325mg/day, any anticoagulant or anti-platelet drug use such as heparin or warfarin, antioxidant use except vitamin E up to 2000 IU/day and vitamin C up to 500mg/day

Design outcomes

Primary

Measure	Time frame
Patients score in MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating) scale. Timepoint: beginning of study, 3 months after drug initiation, 6 months after drug initiation, 9 months after drug initiation. Method of measurement: MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating) scale which is a based on standard questionnaire, interview and neurological examination of the patients.	—

Measure

Time frame

Patients score in MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating) scale. Timepoint: beginning of study, 3 months after drug initiation, 6 months after drug initiation, 9 months after drug initiation. Method of measurement: MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating) scale which is a based on standard questionnaire, interview and neurological examination of the patients.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Ghodsi

Mashhad University of Medical Sciences

Ghodsihr901@mums.ac.ir+98 51 3883 3080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026